Abstract: Techniques for planning resources using block and route information are described. In an example, a computing system determines a demand for item transportation expected during a planning horizon. The computing system determines information about a pre-planned transportation resource available during the planning horizon and costs associated with the pre-planned transportation resource. The computing system uses an optimization model to determine a block having a time length, a tour to transport, during the block, a first portion of the demand using the pre-planned transportation resource, and a second portion of the demand to be transported using an on-demand transportation resource. The computing system indicates, to a first computing device of the pre-planned transportation resource, an assignment of the block to the pre-planned transportation resource.

Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.

Abstract: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.

Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.

Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.

Abstract: The present invention comprises methods and apparatuses for the production or formation of co-crystals. The methods and apparatuses can be used to grind two or more co-crystal components resulting in the formation of co-crystals. The resultant co-crystals can have several uses as disclosed herein.

Abstract: A mixed co-crystal comprising an API, a first co-crystal former, and a second co-crystal former which is isomorphically substitutable with said first co-crystal former is described. A pharmaceutical composition comprising a mixed co-crystal, methods of making mixed co-crystals, and methods of using mixed co-crystals are also described.

Abstract: Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.

Abstract: Methods and systems for the analysis of solid materials are disclosed. The present invention comprises x-ray and Raman analytical techniques and systems which facilitate the rapid characterization of a plurality of solid samples.

Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.

Abstract: The invention provides novel isovaleramide forms. These forms include isovaleramide co-crystals, and solvates, hydrates, co-crystals, and polymorphs thereof. The invention also provides novel compositions comprising these novel forms and one or more suitable carriers. The invention also provides related methods of treatment or prevention. Compositions and methods of the invention have a number of uses, including the treatment or prevention of epilepsy and anxiety.

Abstract: Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.

Abstract: The present invention comprises an organic acid salt of gabapentin, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid. Methods for modulating the solubility and dose response of gabapentin are discussed. Methods of making organic acid salts of gabapentin are also discussed.

Abstract: The present invention comprises methods and apparatuses for the production or formation of co-crystals. The methods and apparatuses can be used to grind two or more co-crystal components resulting in the formation of co-crystals. The resultant co-crystals can have several uses as disclosed herein.

Abstract: The invention relates to new crystalline forms of tiotropium bromide, processes for preparing them and their use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

Abstract: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.

Abstract: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.

Abstract: A mixed co-crystal comprising an API, a first co-crystal former, and a second co-crystal former which is isomorphically substitutable with said first co-crystal former is described. A pharmaceutical composition comprising a mixed co-crystal, methods of making mixed co-crystals, and methods of using mixed co-crystals are also described.

Abstract: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a recrystallization/precipitation retardant and an optional enhancer.

Abstract: The present invention comprises an organic acid salt of gabapentin, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid. Methods for modulating the solubility and dose response of gabapentin are discussed. Methods of making organic acid salts of gabapentin are also discussed.